Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-02-01
1998-10-20
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514725, 514912, A61K 31435, A61K 3107
Patent
active
058246851
ABSTRACT:
Proliferation of retinal pigment epithelium following surgery or trauma is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR) agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epitelium is ameliorated witha therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 .mu.g, or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.
REFERENCES:
patent: 5234926 (1993-08-01), Chandraratna
Campochiaro Peter A.
Chandraratna Roshantha A.
Nagpal Sunil
Wheeler Larry A.
Allergan
Fay Zohreh
The Johns Hopkins University School of Medicine
LandOfFree
Method of preventing proliferation of retinal pigment epithelium does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preventing proliferation of retinal pigment epithelium, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preventing proliferation of retinal pigment epithelium will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-244618